Citation Impact
Citing Papers
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
2020
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Filgotinib: First Approval
2020
AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging
2019
The Binary Classification of Protein Kinases
2021
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
2017
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
2020
Myasthenia gravis
2019 Standout
Ulcerative colitis
2020 Standout
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
2019
Myasthenia gravis with antibodies to MuSK: an update
2017
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials
2018
Works of Ann Biehl being referenced
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017